Tempus’ automated alerts boost patient outcomes in valvular heart disease
Tempus and Medtronic have uncovered the potential of artificial intelligence (AI)-driven electronic clinician notifications (ECNs) in improving outcomes and supporting…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
Medtronic’s OmniaSecure defib lead nets another FDA approval
Irish medtech giant Medtronic has secured another US approval for its OmniaSecure defibrillation lead, expanding its use to placement in…
-
Vinay Prasad to leave the FDA again
Vinay Prasad is once again set to depart from his role at the US Food and Drug Administration (FDA), after…
-
Daiichi and GAIA join forces to commercialise digital cardiovascular therapy
Daiichi Sankyo’s European faction and health technology company GAIA have banded together to commercialise a digital therapeutic designed to support…
-
Polares secures $50m in Series C to advance mitral transcatheter
Polares Medical has secured $50m through a Series C financing round to further support the development of its novel cardiac…
-
RadNet bolsters clinical AI capabilities with Gleamer acquisition
Diagnostic imaging specialist RadNet has agreed to acquire French clinical artificial intelligence (AI)-focused company, Gleamer, for up to €230m ($267.2m).…
-
BlueWind’s Revi urinary incontinence device demonstrates three-year efficacy
BlueWind Medical’s Revi implantable tibial neuromodulation (ITNM) system has demonstrated sustained efficacy and safety at the three-year mark in a…
-
Medtronic’s diabetes business MiniMed looks for $784m in US IPO
Diabetes specialist MiniMed has launched an initial public offering (IPO) to bolster its capital reserve amid its ongoing split from…
-
MiraDx expands predictive oncology testing arsenal with Prostox Standard
California-based molecular diagnostics company MiraDx has added Prostox Standard to its portfolio – marking another US launch in the company’s…
-
Guardant Health acquires MetaSight amid positive 2026 financial outlook
Cancer diagnostics specialist Guardant Health has completed its $149m acquisition of health technology company, MetaSight Diagnostics, as the company gears…